This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by KRIEG, R. J. Articles by CRONIN, M. J. Search for Related Content PubMed PubMed Citation Articles by KRIEG, R. J. Articles by CRONIN, M. J.

β-Adrenergic Stimulation of Growth Hormone (GH) Release in Vivo, and Subsequent Inhibition of GHReleasing Factor-Induced GH Secretion^*

RICHARD J. KRIEG, SUSAN N. PERKINS, JAMES H. JOHNSON, JOHN P. ROGERS, AKIRA ARIMURA and MICHAEL J. CRONIN

Department of Anatomy, Medical College of Virginia Richmond, Virginia 23298
the Department of Physiology, University of Virginia (S.N.P., M.J.C.) Charlottesville, Virginia 22908
the Department of Medicine, Tulane University (A.A.) New Orleans, Louisiana 70112

Address all correspondence and requests for reprints to: Richard J. Krieg Jr., Ph.D., Department of Anatomy, Medical College of Virginia, Box 709, MCV Station, Richmond, Virginia 23298.

Abstract

In vivo and in vitro studies of β-adrenergic influences on GH secretion have produced apparently conflicting data in which the In vivo effect seems to be inhibitory and the in vitro effect to be stimulatory. The present studies were designed to observe the In vivo effect of isoproterenol (ISO), a β- adrenergic agonist, on 1) GH release during a brief interval after intraatrial infusion, and 2) GH release in response to GRF infused 10 min after ISO. ISO was found to stimulate GH release in both intact and hypothalamus-lesioned animals within 2 min after infusion, but GH returned to control levels within 10 min. ISO also profoundly inhibited the release of GH in response to GRF. Pretreatment of animals with somatostatin (SRIF) antiserum prevented the inhibitory action of ISO on GRF-induced GH release. No change in peripheral levels of SRIF was detected. Also, there was no suppression of GRF-induced GH release by ISO when the treatments were applied in vitro to dispersed perifused pituitary cells. These data show that β-adrenergic systems can stimulate a rapid but brief release of GH In vivo, and that the subsequent inhibitory action on GRF-induced GH release might be by means of SRIF release. (Endocrinology 122: 531–537, 1988)

Footnotes

^* This work was supported by a Biomedical Research Support Grant from the Medical College of Virginia (to R.J.K.), and Grant AM-32632 and Research Career Development Award 1K04-NS-00601 (to M.J.C.).

Present address: Department of Medicine, Division of Endocrinology, Stanford University Medical Center, Stanford, California 94305.

Present address: Pharmacological Sciences, Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, California 94080.

Received September 24, 1987.

This article has been cited by other articles:

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]